Anti-Parasitic Drug Discovery in Epigenetics

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1074016

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Parasitic infections are a significant global health problem, resulting in more than a million deaths annually. Unfortunately there is no licensed vaccine available for any human parasitic infection, and in many cases current drugs suffer from issues of parasite drug resistance. To address this problem this project brings together leading researchers from the European Union, Brazil, and Australia to discover and develop new types of drugs for four major human parasitic diseases: schistosomiasis, leishmaniasis, Chagas disease and malaria.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2016

Funding Scheme: Targeted Calls

Funding Amount: $272,144.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical Parasitology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

drug discovery | epigenetics | leishmaniasis | malaria therapy | medicinal chemistry | parasite | schistosomiasis | trypanosomiasis

Related Links